Combination of Sotyktu and Enstilar for Plaque Psoriasis

Inclusion Criteria:

Male or female adult ≥ 18 years of age;
Diagnosis of chronic plaque-type psoriasis

Moderate to severe plaque type psoriasis as defined at baseline by:

BSA affected by plaque-type psoriasis of 10% or greater
PGA score of 3 or greater
PASI ≥ 12.
Able and willing to give written informed consent prior to performance of any study-related procedures Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis.

Exclusion Criteria:

Other than psoriasis, any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is uncontrolled.
Forms of psoriasis other than chronic plaque-type (e.g., Pustular erythrodermic and/or guttate psoriasis) or drug induced psoriasis
Use of oral systemic medications or PUVA phototherapy for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin and cyclosporine).

Prior use of biologics within the following periods:

Etanercept - 4 weeks
Adalimumab or certolizumab pegol - 8 weeks
IL-17 antagonists - 16 weeks
Ustekinumab or IL-23 pathway inhibitors - 24 weeks
Other biologics - 5 half-lives
Patient used topical therapies or UVB phototherapy to treat psoriasis within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).